newsfilter
← Latest News
GlobeNewswire·

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase 3 RASolute 302 resultsRapidly implemented U.S. Expanded Access Program for